Meningeal metastasis is a fatal complication of breast cancer that affects 5-8% of patients. When cancer cells seed in the meninges, their subsequent growth results in severe neurological complications involving the cranial nerves, cerebrum and spinal cord, limiting life expectancy to less than 4 months. The incidences of meningeal metastases increase with prolonged lifespan resulting from treatment advances for primary breast cancer and their metastases. Currently, there is no cure. Aggressive multimodal therapies such as radiation and chemotherapy (intra-cerebrospinal fluid (CSF) and systemic) are ineffective. Therapeutic agents are often quickly cleared from the CSF, while higher doses that can achieve a therapeutic response are highly toxic. The secure guarding of the subarachnoid space by the blood-brain barrier on one side and the blood-CSF barrier on the other prevents chemotherapy from reaching cancer cells in the meninges. These challenges with treating meningeal metastases highlight the urgent need for a new therapeutic modality. An ideal treatment would be an agent that avoids rapid clearance, remains within the CSF, reaches the meninges and selectively destroys tumor cells. Replication conditional oncolytic herpes simplex virus type 1 (HSV-1) may be effective in this regard. Viral oncolysis, the destruction of cancer cells by replicating virus, is under clinical investigation for cancers that are unresponsive to current therapies. It is based on the model of multiple cycles of lytic virus replication in cancer cells that amplify the injected dose. The therapeutic potential of oncolytic HSV-1 for breast cancer meningeal metastases is discussed here. HSV-1 could be a potential novel treatment for meningeal metastases that can be translated to the clinic.
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MENINGEAL METASTASIS IS A FATAL COMPLICATION OF BREAST CANCER
Meningeal metastasis, also known as carcinomatous meningitis or leptomeningeal metastases, is a fatal complication of breast cancer that results when cancer cells infiltrate the subarachnoid space. Their subsequent growth in the meninges results in severe functional impairment of the central nervous system (CNS) and spinal cord, leading to cachexia, speech disturbances, limb weakness, bradykinasia and paralysis. These symptoms, often irreversible, contribute to a poor prognosis with life expectancy of less than 4 months. 1 Breast cancer is the most common solid tumor to colonize in the meninges, followed by lung cancer and melanoma, with its onset and progression determined by tumor histology and cancer subtypes. Infiltrating lobular breast cancers and those positive for HER2 (human epidermal growth factor receptor 2) and negative for estrogen receptor and progesterone receptor or negative for all three receptors (HER2, estrogen receptor and progesterone receptor) are at greatest risk of developing meningeal metastases. In a study of 118 breast cancer patients with meningeal metastases, 40.5% were triple-negative, out of which 35% had lobular histopathology while 37.5% and 22% had luminal A subtype and luminal B with positive HER2, respectively. 2 Meningeal metastases are diagnosed in approximately 5% of breast cancer patients. The incidence is greater, about 20%, when clinically undiagnosed cases at autopsy are included. 3 According to the American Cancer Society, 232 670 new cases of breast cancer will be diagnosed in the United States in 2014 with a predicted 40 000 deaths. Successful treatment advances have extended the lifespan of patients with primary breast cancer and their metastases. With prolonged survival, the incidence of meningeal metastases that were previously undiagnosed is increasing. Newer molecular imaging techniques such as Gadolinium (Gd) enhanced magnetic resonance imaging (MRI) allow precise diagnosis of meningeal tumor bypassing the need for routine CSF analysis for cancer cells. As such, Gd-MRI accounts for cases that were previously overlooked. The increasing incidences of meningeal metastases pose a challenge in treating the disease as currently there is no cure.
CHALLENGES WITH CURRENT THERAPIES FOR MENINGEAL METASTASES
Several treatment options such as surgery, systemic chemotherapy, site-specific radiotherapy and intra-CSF chemotherapy are considered for meningeal metastases. Most often they are ineffective and used for palliative therapy. Although systemic chemotherapy has had success in treating primary and systemic breast cancer metastases, the concentration required to achieve a therapeutic dose in CSF is intolerably toxic. Local treatment deliveries such as intra-thecal injections have shown some promise. Several molecular therapies such as Trastuzumab delivered intra-thecally are currently under investigation in the clinic. 4 The median overall survival for patients with meningeal metastases is 4-6 weeks. Despite aggressive multimodal therapies, the median overall survival is 2-3 months. 5 Current treatments for meningeal metastases are faced with multiple challenges. First is the inadequate penetration of drug concentrations into the subarachnoid space due to the secure guarding by the blood-brain barrier and the blood-CSF barrier. As a result, cancer cells continue their unchecked proliferation despite attempted therapy. Second, chemotherapy that enters the CSF is rapidly cleared by protein pumps. Third, doses of chemotherapy that are required to achieve substantial tumor cell destruction are severely neuro-toxic. These challenges demand an urgent need for new therapeutic interventions for meningeal metastases. An ideal treatment would be an agent that avoids rapid clearance, remains within the CSF, reaches the meninges and selectively destroys tumor cells. In this context, oncolytic, replication conditional HSV-1 surgically delivered would be a novel therapeutic option.
ONCOLYTIC HSV-1 AS A THERAPEUTIC OPTION FOR MENINGEAL METASTASES
The destruction of cancer cells by replicating viruses or viral oncolysis is currently under investigation for cancer therapy. 6 This approach is based on lytic virus replication once it infects a cancer cell. Progeny virions that are released at the end of a replication cycle infect neighboring cancer cells to begin another wave of lytic replication. The cycles continue until the cancer cells are destroyed or the virus is eliminated by the host immune system. With each replication cycle, the initial virus dose is amplified. Selective and robust virus replication in cancer cells rather than in normal cells defines the safety and efficacy of viral oncolysis. 7 Of the many oncolytic viruses, several characteristics of HSV-1 render it more attractive for oncolytic therapy. These include its well-characterized large genome which allows for genetic modifications, non-integration of viral DNA into the host genome and high infectivity in target tissues. HSV-1 is relatively safe for human use as it is widely prevalent in the population and rarely causes severe medical disease. Sensitivity of HSV-1 mutants to antiherpetic drugs such as acyclovir and gancyclovir provide added safety if the need arises.
Replication conditional oncolytic HSV-1 mutants have been genetically engineered to enable their preferential lytic replication in cancer cells rather than in normal cells. 8 Some mutants (hrR3, rRp450, G207) have been created by inactivating the U L gene segment which codes for the ICP6 gene product ribonucleotide reductase (required for replication). Others (G207, HSV1716 and OncoVexGM-CSF) have been created by deleting the Ɣ134.5 gene segment that codes for the ICP34.5 neuro-virulence factor (required for overcoming host inhibitory machinery). Due to the inactivated ICP6 gene hrR3, rRp450 and G207 replicate preferentially in tumor cells that complement the absent ICP6 gene product with elevated nucleotide pools. Similarly G207 and HSV1716 replicate preferentially in tumor cells with a defective PKR pathway that does not inhibit virus protein synthesis. The cytochrome P450 transgene in rRp450 enables bio-activation of the pro-drug cyclophosphamide.
The ability of HSV-1 to enhance host immunity upon re-challenge is advantageous for oncolytic efficiency. Once re-challenged the virus inhibits tumor growth by cytotoxic T lymphocyte-mediated antitumor immunity. Antitumor immunity has been enhanced by incorporating coding sequences for interleukin-12 or granulocyte-macrophage colony-stimulating factor (GM-CSF) into the viral genome such as in OncoVexGM-CSF. G47Δ triple mutant based on the G207 backbone has an added deletion of the α47 gene product (ICP47) which reverses major histocompatibility complex class I downregulation and initiates host immune responses to virus infection. 8 The spontaneously occurring attenuated HSV-1 mutant HF10 has strong antitumor activity in human and mouse breast cancer cell lines and induces tumor immunity in animal models. In the clinic, HF10 has induced tumor immunity in patients with recurrent breast cancer and lysis of cutaneous metastases in breast cancer patients. 9 Compared with other HSV-1 mutants such as hrR3 that exert cytopathic effect, HF10 induces syncytia formation. The HSV-1 mutant NV1066 which carries the transgene for enhanced green fluorescent protein, has shown substantial lysis of triplenegative breast cancer cell lines in vitro and in vivo. 10 Several oncolytic HSV-1 are in clinical trials. A phase I trial of HF10 is ongoing for refractory head and neck cancer and solid tumors with superficial lesions (NCT01017185). A phase I trial for refractory non-central nervous system solid tumors is addressing the safety of intra-tumor HSV-1716 (NCT00931931). The safety and efficacy of G207 has been confirmed for recurrent brain cancer alone (NCT00028158) or in combination with radiation (NCT00157703) attributing treatment efficacy to intra-tumor virus replication and host immune response. Oncolytic HSV-1 is also under investigation for liver metastases in a recently completed phase I trial for the safety and efficacy of a single dose of NV1020 (NCT00149396). In a phase I trial, we are investigating the highest tolerable dose of rRp450, its pharmacokinetics and the antitumor effect against primary or secondary liver tumors (NCT01071941).
INVESTIGATIONS OF ONCOLYTIC HSV-1 FOR BREAST CANCER MENINGEAL METASTASES
We investigated the potential therapeutic effect of oncolytic HSV-1 on breast cancer meningeal metastases. Compared with conventional chemotherapeutic agents that have a particle size of less than 1 nm, the relatively large-sized HSV-1 (140 nm) will avoid its rapid clearance from the CSF. In a meningeal metastases model developed and characterized in our laboratory, the virus remained in the CSF for 48 h after intra-ventricular delivery. This time period would be sufficient for the virus to infect tumor cells as they disseminate to sites of metastases via the CSF. As such, oncolytic HSV-1 is poised to target these tumors compared with chemotherapy, which have a half-life of 1-4 h such as with thiotepa and Cytarabine often administered for meningeal metastases, or Methotrexate with a half-life of 4-14 h with alphaand beta-phase clearance times of 1.6 and 6.7 h.
Our initial investigations were conducted in nude BALB/C mice where meningeal metastases were induced by stereotactic injection of MDA-MB-231 human breast cancer cells into the right lateral ventricle. These cells were stably transfected to express Rluc for bioluminescence imaging. We studied the onset and growth of meningeal metastases in the brain and spinal cord with sequential Gd-MRI. Tumor growth quantified with Gd uptake on MRI occurred as an initial lag phase followed by an exponential phase over the 3 weeks. A similar growth pattern was observed with Rluc bioluminescence signal quantification. By the third week (latter stages of disease), tumor had accumulated at the base of the brain accompanied with symptoms involving the cranial and spinal nerves. These were loss of appetite, loss of movement, hind leg paralyses, bradykinesia, ataxia, cachexia and weight loss.
In the oncolytic HSV-1 treatment protocol, replication conditional HSV mutant (that expresses Fluc) was injected into the right lateral ventricle. This mutant also expresses LacZ and is defective in ICP6 gene. Virus was injected 12 days after tumor inoculation targeting the early growth phase. Tumor response to lytic replication was imaged with Gd-MRI over time. A dramatic decrease in Gd contrast uptake was observed in the base of the brain 4 days after virus injection. This decrease in Gd uptake was evident even 9 days after a single virus injection. In contrast a high Gd uptake was seen in the brains with non-treated tumors. MRI provides anatomical distribution of tumor and its destruction following oncolytic virus therapy. Observed reductions of Gd uptake on MRI corresponded to changes on histopathology. Similarly, a reduction in Rluc bioluminescence was seen in the treated animals compared with un-treated tumor animals. Virus replication in tumors was imaged with Fluc bioluminescence and {9-(4-18F-fluoro-3-[hydroxymethyl]butyl)guanine}-positron emission tomography ( 18F FHBG-PET). As the virus retains its thymidine kinase gene, it can phosphorylate the guanine derivative FHBG. The phosphorylated 18F FHBG that is trapped inside the cell is detected with PET. A high Fluc signal distribution in the entire brain was identified immediately (24 h) after virus injection. By 48-72 h, the virus was localized to smaller regions, which were sites of virus replication. FHBG-PET scans revealed a similar virus distribution from 24 to 72 h. Even after 7 days, virus was identified in the treated brains with FHBG-PET ( Figure 1) .
With intervention at the early phase of tumor growth, a reduction in tumor burden at the base of the brain was identified along with prevention of further tumor progression. This was accompanied by gradual improvement in existing neurological symptoms such as bradykinesia, ataxia, anorexia and paralysis that accompany a heavy tumor burden. The mice treated with the oncolytic HSV-1 showed no further weight reduction, whereas untreated mice lost considerable weight. Virus was localized with immunohistochemical staining for HSV-TK in the brains ex vivo, and the results corresponded with that of PET and Fluc scans for replicating virus. The treated mice survived until 4 weeks (1 week beyond control mice), with a response rate of 67.7% following a single virus dose of 1 × 10 7 plaque-forming units. A good response was also seen following intervention at exponential phase of tumor growth. Virus was injected 16 days after tumor inoculation to target the late growth phase. A reduction in tumor growth with Gd-MRI and Rluc was observed over time although not as dramatic as when treated at the early phase of tumor growth. The mice survived for an additional 4 days compared with control mice, with a response rate of 42.8%.
CONCLUSION
In our ongoing investigations of oncolytic HSV-1 therapy for meningeal metastases, we have observed a reduction in tumor burden in the brain and spinal cord accompanied with prolonged survival. Virus is retained in the CSF where titer is amplified by preferential replication in cancer cells. These initial observations are encouraging as they demonstrate targeted tumor response with minimal toxicity, inhibition of life-threatening disease progression and prolonged survival. As such, replication conditional oncolytic HSV-1 can be an effective novel treatment for breast cancer meningeal metastases that can be translated into the clinic. 
